Order Article Reprints

Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, et al. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers. 2021; 13(22):5758. https://doi.org/10.3390/cancers13225758

Aughton, Karen, Nils O. Elander, Anthony Evans, Richard Jackson, Fiona Campbell, Eithne Costello, Christopher M. Halloran, John R. Mackey, Andrew G. Scarfe, Juan W. Valle, and et al. 2021. "hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA" Cancers 13, no. 22: 5758. https://doi.org/10.3390/cancers13225758

Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., Halloran, C. M., Mackey, J. R., Scarfe, A. G., Valle, J. W., Carter, R., Cunningham, D., Tebbutt, N. C., Goldstein, D., Shannon, J., Glimelius, B., Hackert, T., Charnley, R. M., Anthoney, A., ... Greenhalf, W. (2021). hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 13(22), 5758. https://doi.org/10.3390/cancers13225758